<?xml version="1.0" encoding="utf-8"?>
<export-example>
  <doc>
    <id>2431</id>
    <completedYear>2023</completedYear>
    <publishedYear>2023</publishedYear>
    <thesisYearAccepted/>
    <language>eng</language>
    <pageFirst>3</pageFirst>
    <pageLast>10</pageLast>
    <pageNumber>8</pageNumber>
    <edition/>
    <issue>4</issue>
    <volume>26</volume>
    <type>article</type>
    <publisherName>Elsevier BV</publisherName>
    <publisherPlace/>
    <creatingCorporation/>
    <contributingCorporation/>
    <belongsToBibliography>1</belongsToBibliography>
    <completedDate>--</completedDate>
    <publishedDate>--</publishedDate>
    <thesisDateAccepted>--</thesisDateAccepted>
    <title language="eng">Across-Country Variations of Real-World Data and Evidence for Drugs</title>
    <abstract language="eng">Objectives: This study aimed to describe the role of real-world data (RWD) and real-world evidence (RWE) in health technology assessment (HTA) in 5 European countries and to identify the hurdles to the acceptance of RWE and suggest directions toward its more effective use.&#13;
&#13;
Methods: Authors from France, Germany, Italy, and Sweden used a common template to extract evidence. For England, the Cancer Drugs Fund was described and analyzed as a particular model for the use of RWD to provide evidence for coverage decisions and managed entry agreements.&#13;
&#13;
Results: In all countries except Germany, HTA bodies acknowledged the relevance of RWD/RWE to address postlaunch uncertainties. In Germany, evidence from randomized controlled trials remains the gold standard, and evidence based on RWD is generally rejected. Multiple sources of RWD exist, but the quality, the immediate relevance of existing sources, and their interoperability limit their adaptation to the specifics of a given drug. This leads to skepticism about the validity of the evidence. Timing is also a key issue: the production of evidence may not be synchronized with the HTA and pricing bodies' agendas. The Cancer Drugs Fund case emphasizes that a strong partnership among all stakeholders and a pragmatic use of existing data, alongside clinical evidence provided by companies, are key success factors.&#13;
&#13;
Conclusions: A continuous investment in national health information systems is a key issue for providing valid RWE. Processes and aids to guide the acceptability and usage of RWE derived from pairing between sources and questions are essential.</abstract>
    <parentTitle language="eng">Value in Health</parentTitle>
    <subTitle language="eng">a 5-European-Country Study</subTitle>
    <identifier type="issn">1098-3015</identifier>
    <identifier type="doi">10.1016/j.jval.2023.01.009</identifier>
    <enrichment key="opus_doi_flag">true</enrichment>
    <enrichment key="opus_import_data">{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,9,11]],"date-time":"2024-09-11T04:44:40Z","timestamp":1726029880986},"reference-count":13,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"vor","delay-in-days":366,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","valueinhealthjournal.com","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Value in Health"],"published-print":{"date-parts":[[2023,4]]},"DOI":"10.1016\/j.jval.2023.01.009","type":"journal-article","created":{"date-parts":[[2023,1,26]],"date-time":"2023-01-26T08:09:25Z","timestamp":1674720565000},"page":"3-10","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"S","title":["Across-Country Variations of Real-World Data and Evidence for Drugs: A 5-European-Country Study"],"prefix":"10.1016","volume":"26","author":[{"given":"G\u00e9rard","family":"de Pouvourville","sequence":"first","affiliation":[]},{"given":"David","family":"Cunningham","sequence":"additional","affiliation":[]},{"given":"Frank-Ulrich","family":"Fricke","sequence":"additional","affiliation":[]},{"given":"Peter","family":"Lindgren","sequence":"additional","affiliation":[]},{"given":"Lorenzo","family":"Mantovani","sequence":"additional","affiliation":[]},{"given":"Linda A.","family":"Murphy","sequence":"additional","affiliation":[]},{"given":"Oriol","family":"Sol\u00e0-Morales","sequence":"additional","affiliation":[]},{"given":"Jorge","family":"Mestre-Ferrandiz","sequence":"additional","affiliation":[]},{"given":"Ron","family":"Akehurst","sequence":"additional","affiliation":[]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.jval.2023.01.009_bib2","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1177\/0020731421997094","article-title":"How the United Kingdom controls pharmaceutical prices and spending: learning from its experience","volume":"51","author":"Rodwin","year":"2021","journal-title":"Int J Health Serv"},{"key":"10.1016\/j.jval.2023.01.009_bib3","author":"B\u00e9gaud"},{"issue":"4","key":"10.1016\/j.jval.2023.01.009_bib5","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/j.healthpol.2020.02.002","article-title":"Risk sharing in managed entry agreements\u2014a review of the Swedish experience","volume":"124","author":"Andersson","year":"2020","journal-title":"Health Policy"},{"issue":"3","key":"10.1016\/j.jval.2023.01.009_bib6","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1007\/s40273-017-0596-z","article-title":"Using real-world data in health technology assessment (HTA) practice: a comparative study of five HTA agencies","volume":"36","author":"Makady","year":"2018","journal-title":"Pharmacoeconomics"},{"issue":"12","key":"10.1016\/j.jval.2023.01.009_bib7","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1056\/NEJMoa0905561","article-title":"Dabigatran versus warfarin in patients with atrial fibrillation","volume":"361","author":"Connolly","year":"2009","journal-title":"N\u00a0Engl J Med"},{"issue":"10","key":"10.1016\/j.jval.2023.01.009_bib8","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJMoa1009638","article-title":"Rivaroxaban versus warfarin in nonvalvular atrial fibrillation","volume":"365","author":"Patel","year":"2011","journal-title":"N\u00a0Engl J Med"},{"issue":"11","key":"10.1016\/j.jval.2023.01.009_bib9","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1056\/NEJMoa1107039","article-title":"Apixaban versus warfarin in patients with atrial fibrillation","volume":"365","author":"Granger","year":"2011","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"10.1016\/j.jval.2023.01.009_bib10","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1007\/s40256-019-00359-z","article-title":"Comparative real-life effectiveness and safety of dabigatran or rivaroxaban vs. vitamin K antagonists: a high-dimensional propensity score matched new users cohort study in the French National Healthcare Data System SNDS","volume":"20","author":"Blin","year":"2020","journal-title":"Am J Cardiovasc Drugs"},{"issue":"9","key":"10.1016\/j.jval.2023.01.009_bib11","doi-asserted-by":"crossref","first-page":"2469","DOI":"10.1161\/STROKEAHA.119.025824","article-title":"Effectiveness and safety of rivaroxaban 15 or 20 mg versus vitamin K antagonists in nonvalvular atrial fibrillation","volume":"50","author":"Blin","year":"2019","journal-title":"Stroke"},{"issue":"4","key":"10.1016\/j.jval.2023.01.009_bib12","doi-asserted-by":"crossref","first-page":"286","DOI":"10.3109\/21681805.2016.1172254","article-title":"Value of treatment in clinical trials versus the real world: the case of abiraterone acetate (Zytiga) for postchemotherapy metastatic castration-resistant prostate cancer patients in Sweden","volume":"50","author":"Svensson","year":"2016","journal-title":"Scand J Urol"},{"issue":"11","key":"10.1016\/j.jval.2023.01.009_bib13","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1016\/S1470-2045(19)30456-5","article-title":"Progress in cancer survival, mortality, and incidence in seven high-income countries 1995-2014 (ICBP SURVMARK-2): a population-based study","volume":"20","author":"Arnold","year":"2019","journal-title":"Lancet Oncol"},{"issue":"12","key":"10.1016\/j.jval.2023.01.009_bib15","first-page":"S2","article-title":"Data governance for real-world data management: optimizing its use in health technology assessment and regulatory decision making","volume":"24","author":"Sigur\u00f0ard\u00f3ttir","year":"2021","journal-title":"Value Health"},{"issue":"4S","key":"10.1016\/j.jval.2023.01.009_bib16","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.jval.2023.01.007","article-title":"Structure and content of a taxonomy to support the use of real-world evidence by health technology assessment practitioners and healthcare decision makers","volume":"26","author":"Murphy","year":"2023","journal-title":"Value Health"}],"container-title":["Value in Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1098301523000153?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1098301523000153?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,5,11]],"date-time":"2024-05-11T07:53:36Z","timestamp":1715414016000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1098301523000153"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4]]},"references-count":13,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,4]]}},"alternative-id":["S1098301523000153"],"URL":"http:\/\/dx.doi.org\/10.1016\/j.jval.2023.01.009","relation":{},"ISSN":["1098-3015"],"issn-type":[{"value":"1098-3015","type":"print"}],"subject":[],"published":{"date-parts":[[2023,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Across-Country Variations of Real-World Data and Evidence for Drugs: A 5-European-Country Study","name":"articletitle","label":"Article Title"},{"value":"Value in Health","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jval.2023.01.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"name":"copyright","label":"Copyright"}]}}</enrichment>
    <enrichment key="local_crossrefDocumentType">journal-article</enrichment>
    <enrichment key="local_crossrefLicence">https://www.elsevier.com/tdm/userlicense/1.0/</enrichment>
    <enrichment key="local_import_origin">crossref</enrichment>
    <enrichment key="local_doiImportPopulated">PersonAuthorFirstName_1,PersonAuthorLastName_1,PersonAuthorFirstName_2,PersonAuthorLastName_2,PersonAuthorFirstName_3,PersonAuthorLastName_3,PersonAuthorFirstName_4,PersonAuthorLastName_4,PersonAuthorFirstName_5,PersonAuthorLastName_5,PersonAuthorFirstName_6,PersonAuthorLastName_6,PersonAuthorFirstName_7,PersonAuthorLastName_7,PersonAuthorFirstName_8,PersonAuthorLastName_8,PersonAuthorFirstName_9,PersonAuthorLastName_9,PublisherName,TitleMain_1,Language,TitleParent_1,PageNumber,PageFirst,PageLast,Issue,Volume,CompletedYear,IdentifierIssn,Enrichmentlocal_crossrefLicence</enrichment>
    <enrichment key="Reviewstatus">Begutachtet/Reviewed</enrichment>
    <enrichment key="opus.source">doi-import</enrichment>
    <enrichment key="opus.doi.autoCreate">false</enrichment>
    <enrichment key="opus.urn.autoCreate">false</enrichment>
    <licence>Creative Commons - CC BY - Namensnennung 4.0 International</licence>
    <author>Gérard de Pouvourville</author>
    <author>David Cunningham</author>
    <author>Frank-Ulrich Fricke</author>
    <author>Peter Lindgren</author>
    <author>Lorenzo Mantovani</author>
    <author>Linda A. Murphy</author>
    <author>Oriol Solà-Morales</author>
    <author>Jorge Mestre-Ferrandiz</author>
    <author>Ron Akehurst</author>
    <subject>
      <language>eng</language>
      <type>uncontrolled</type>
      <value>country comparison; real-world data; real-world evidence</value>
    </subject>
    <collection role="institutes" number="">Fakultät Betriebswirtschaft</collection>
  </doc>
</export-example>
